摘要
目的观察单唾液酸四己糖神经节苷脂治疗进展性缺血性脑卒中的疗效。方法选择106例发病在1248 h,病情呈进行性加重的进展性缺血性脑卒中患者,随机分为治疗组和对照组,每组53例。3个疗程后作疗效判定,B I评分评估其日常生活能力及意识水平。并监测治疗前后血清S100β蛋白动态水平的变化。结果3个疗程后治疗组总有效率为92.5%,明显高于对照组的81.1%（P〈0.05）;治疗组治疗后第7、14及21天患者的B I评分均明显高于对照组,血清S100β蛋白水平明显低于对照组（P〈0.05）。结论单唾液酸四己糖神经节苷脂能有效地治疗进展性缺血性脑卒中,临床疗效确切、安全,值得在临床推广应用。
Aim To observe the clinical effect of monosialotetrahexosylganglioside in treatment of ischemic stroke. Methods 106 cases of ischemic stroke were randomly divided into two groups,experimental group and control group,53 cases in each group.BI score were applied to assess the activities of daily living and level of awareness after a course of treatment to determine the efficacy.And serum S100β protein level changes were monitored before and after treatment. Results After one course of treatment,the total effective rate in experimental treatment group was 92.5% and 81.1% in the control group.BI score of the treatment group was significantly higher than that of the control group at 7th,14th and 21th days,and the differences were statistically significant（P〈0.05）.Compared with the control group,the experimental group achieved better nurological function after treatment,and the difference was statistically significant（P〈0.05）.The serum S100β protein levels in the treatment group decreased gradually at the 7th,14th and 21th days after treatment,significantly lower than the concentration of the same group before treatment,but also significantly lower than that of the control group.The differences were statistically significant（P〈0.05）. Conclusion Monosialotetrahexosylganglioside was effective in treatment of ischemic stroke,and without side effect,and deserved clinical application.
出处
《中国动脉硬化杂志》
CAS
CSCD
北大核心
2009年第11期944-946,共3页
Chinese Journal of Arteriosclerosis
基金
河北省保定市科技攻关计划(08ZF072.2008-2009)
